AcuCort's Phase IV Study Results Published
AcuCort's Phase IV clinical study results for Zeqmelit® have been published in the Journal of Market Access & Health Policy. The study reported positive outcomes for the oral film formulation.
Results from AcuCort's Phase IV clinical study with Zeqmelit® have been published in the peer-reviewed scientific journal Journal of Market Access & Health Policy. The study reports positive outcomes for Zeqmelit® oral film and provides valuable insight into patient perceptions of glucocorticoid treatment for moderate to severe acute allergic reactions, focusing on accessibility, confidence, and effectiveness.
The published study, ZEQ001, included 50 patients, with 44 completing the trial. Conducted as an open-label, low-intervention study, ZEQ001 offers further understanding of Zeqmelit's real-world clinical use and patient experiences with the treatment. These findings support AcuCort's objective to enhance the management of acute allergic reactions.
Zeqmelit® is an oral film developed by AcuCort, designed for oral administration to facilitate glucocorticoid absorption. The publication of this study reinforces the company's commitment to building medical evidence for its products and improving patient treatment experiences.